References
- Rotimi VO, Khoursheed M, Brazier JS, Jamal WY. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin Microbiol Infect 1999; 5: 166-169.
- Ueno K, Watanabe K, Bando K, Kato N. The antimicro-bial susceptibility of recent clinical isolates of Bacteroides frag-ilis group. Clin Infect Dis 1993; 6 (Suppl 4): 382–386.
- Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC: Susceptibility of 497 clinical isolates of Gram-negative anaerobes to trovafloxacin and eight other antibiotics. J Chemother 1999; 11: 349–356.
- Peláez T, Alcalá L, Martinez-Sanchhez L, et al. Metronidazole resistance in Clostridium difficile: a new emerging problem? In program and abstracts of the 38th Interscience Conference on Antimicrobial Agents Chemotherapy, American Society for Microbiology, Washington, D.C. 1998. Abstr. E-173, p.219.
- Watanabe K, Ueno K, Kato N, et al. In vitro suscepti-bility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan. Eur J Clin Microbiol Infect Dis 1992; 11: 1069–1073.
- Jacobs MR, Spangler SK, Appelbaum PC. Beta-lacta-mase production and susceptibility of US and European anaer-obic Gram-negative bacilli to beta-lactam and other agents. Eur J Clin Microbiol Infect Dis 1992; 11: 1081–1093.
- Perry CM, Jarvis B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525–51.
- Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, Denbesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357 (9263): 1179.
- Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid. Clin Infect Dis 2000; 31 (Suppl 4): 144–149.
- Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001; 85 (1): 1–17.
- Peláez T, Alonso R, Perez C, Alcalá L, Cuevas O, Souza E. In vitro activity of linezolid against Clostridium diffi-cile. Antimicrob Agents Chemother 2002; 46: 1617–1618.
- Edlund C, Oh O, Nord C. In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin Microbiol Infect 1999; 5: 51–53.
- Phillips OA, Udo EE, Ali AAM, Al-Hassawi N. Synthesis and antibacterial activity of 5-substituted oxazolidi-nones. Bioorg Med Chem 2003; 11 (1): 5–11.
- Summanen P, Baron EJ, Citron DM, Strong CA, Wexler HM, Finegold SM. Wadsworth anaerobic bacteriology manual, 5th edition, Star Publishing Company, 1993.
- National Committee for Clinical Laboratory Standards. Methods for Antimicrobial susceptibility testing for anaerobic bacteria, Approved standard M11-A4, Vol 17, No.22, Villanova; NCCLS, 1997.
- Finegold SM. Overview of clinically important anaer-obes. Clin Infect Dis 1995; 20 (Suppl 2): 205–207.
- Bartlett JG. Clostridium difficile: clinical considera-tions. Rev Infect Dis 1990; 12 (Suppl 2): 243–251.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283–284.